January 2015 Newsletter

January 23, 2015:

2014 in Review: Ophthalmic Ventures Raised a Record $1.7 Billion for Product Development Efforts

At least 11 companies in the industry launched initial public offerings, while only two did so in 2013.

January 23, 2015:

2014 in Review: Mergers, Acquisitions

January 23, 2015:

2014 in Review: Regulatory Approvals for Ophthalmic Drugs

January 23, 2015:

2014 in Review: Regulatory Approvals for Ophthalmic Devices

January 23, 2015:

2014 in Review: Regulatory Highlights from Europe, Japan

January 23, 2015:

2014 in Review: China Approvals

January 23, 2015:

2014 in Review: Cataract Surgery

January 23, 2015:

2014 in Review: Femtosecond Laser Cataract Surgery

January 23, 2015:

2014 in Review: Ultrasonic Phaco

January 23, 2015:

2014 in Review: Refractive Surgery

January 23, 2015:

2014 in Review: Diagnostic Equipment

January 23, 2015:

2014 in Review: Glaucoma Devices

January 23, 2015:

2014 in Review: Retinal Surgery

January 23, 2015:

2014 in Review: Retinal, Glaucoma Pharmaceuticals

January 23, 2015:

2014 in Review: Dry Eye

January 23, 2015:

Newly Discovered Antibiotic Offers Promise to Ophthalmic Industry

Eye surgeons have faced a growing problem of drug resistance, even as use of IVT injections has been increasing rapidly.

January 23, 2015:

Big Pharma’s Interest in Antibiotics Increases

Federal officials have made legislative and regulatory efforts to incentivize the development of these drugs.

January 23, 2015:

Pass-through Status in Place for Omidria, Mitosol

Omidria's reimbursement will be based on the product's wholesale acquisition cost of $400 to $500 per single-use vial.

January 23, 2015:

Price War in Hepatitis C Drugs May Signal Shift in Pharma Pricing, Access

While this battle is outside the confines of ophthalmology, it may have far-reaching implications.

January 23, 2015:

Biosimilars Advance Toward US Market with FDA Panel Recommendation

Ophthalmic companies gearing up in this segment include Pfenex, whose lead program involves a Lucentis biosimilar in Phase I/II clinical study.

January 23, 2015:

Indictment: NECC Drugs Compounded with ‘Appalling Indifference to Human Life’

The Massachusetts facility compounded injectable Avastin and triamcinolone acetonide for ophthalmic use.

January 23, 2015:

Pearson: Valeant Has Put Allergan Bid Behind It

J. Michael Pearson refers to the whole saga as a speedbump and says has no plans to work on another deal with William Ackman.

January 23, 2015:

January 2015 News Briefs

January 23, 2015:

Market Scope Heading to West Coast for AGS Meeting

Social media